Use of extended half life factor VIII products in children with severe hemophilia A on prophylaxis: A single centre experience

被引：0
|
作者：
Komitopoulou, A. [1 ]
Pergantou, H. [1 ]
Mazarakis, M. [1 ]
Kapsimali, Z. [1 ]
Karelioti, E. [1 ]
Dettoraki, A. [1 ]
Platokouki, H. [1 ]
机构：
[1] Aghia Sophia Childrens Hosp, Haemostasis Unit, Haemophilia Ctr, Athens, Greece
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P050
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
    Berntorp, Erik
    Andersson, Nadine G.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (05): : 518 - 525
  • [2] Switch to extended half-life recombinant factor VIII FC in severe hemophilia A patients under prophylaxis. Experience in one centre
    Jimenez, R.
    Nunez, R.
    Jimenez, P.
    Rodriguez-Martorell, F. J.
    Perez-Simon, J. A.
    HAEMOPHILIA, 2018, 24 : 117 - 117
  • [3] Pharmacokinetics of Extended Half- Life Factor VIII Products By myPKFiTR Is Useful for Personalized Treatment in Children with Severe Hemophilia a
    Matsumura, Risa
    Tomioka, Keita
    Nishimura, Shiho
    Mizoguchi, Yoko
    Kawaguchi, Hiroshi
    Kobayashi, Masao
    BLOOD, 2019, 134
  • [4] Extended Half Life Factor VIII in children with haemophilia A: A real life prophylaxis experience guided by population pharmacokinetics
    Ardila, Jesus
    Arias, Diana
    Wilches, Juan
    Martinez, Guiovanna
    Sarmiento, Juan
    Ramos, Gloria
    Grillo, Karina
    HAEMOPHILIA, 2023, 29 : 11 - 12
  • [5] Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
    Mannucci, Pier Mannuccio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 303 - 309
  • [6] Half-life extended factor VIII for the treatment of hemophilia A
    Tiede, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S176 - S179
  • [7] A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors
    Hasan, Esraa Mohamed Ahmed
    Motwani, Jayashree
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : e83 - e89
  • [8] Discrepancies in laboratory assays for extended half-life factor VIII/Factor IX products monitoring: Experience from a single paediatric centre in Argentina
    Sueldo, Rodolfo
    Annetta, Eliana
    Frontroth, Juan
    Cervio, Carolina
    Bianco, Belen
    Sciuccati, Gabriela
    Hepner, Mirta
    HAEMOPHILIA, 2024, 30 : 90 - 91
  • [9] The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States
    Malec, Lynn M.
    Cheng, Dunlei
    Witmer, Char M.
    Jaffray, Julie
    Kouides, Peter A.
    Haley, Kristina M.
    Sidonio, Robert F., Jr.
    Johnson, Kelsey
    Recht, Michael
    White, Gilbert
    Croteau, Stacy E.
    Ragni, Margaret, V
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 960 - 965
  • [10] Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A
    Mullins, E. S.
    Stasyshyn, O.
    Alvarez-Roman, M. T.
    Osman, D.
    Liesner, R.
    Engl, W.
    Sharkhawy, M.
    Abbuehl, B. E.
    HAEMOPHILIA, 2017, 23 (02) : 238 - 246
12345